Identification and mapping of potential partners for the future treatment of non-communicable diseases
| Reference number | |
| Coordinator | BRIGHTER AB (PUBL) - Brighter AB |
| Funding from Vinnova | SEK 200 000 |
| Project duration | October 2016 - April 2017 |
| Status | Completed |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Competence Enhancement in SME - 2016 |
Important results from the project
The global healthcare system is facing enormous economic pressure, which is expected to rise into unsustainable levels in the future. Research and development of new biological medicins for the treatment of chronic diseases is constantly evolving. However, new drug development processes are time consuming and extremely costly. Brighter will streamline drug development process through developing new solutions with one or more potentially identified partners from this project. The solution will also lower medical drug prices as well as improve the treatment process.
Expected long term effects
Brighter has found more than twenty potential partners that might be involved in further development of the Actiste for use in several therapeutic area. The new product (s) will measure biological parameters, the actual medicin injected volume as well as log and share data. The solution has the potential to streamline clinical trials with accurate data for validation and increase efficiency in healthcare through improved communication, increased compliance and patient monitoring outside hospital.
Approach and implementation
In this project Brighter together with the external consult MD Jorge C. Otero has identiferad potential drug candidates that may be relevant for future development of companian devices. Brighter will be working closely with the identified potential partners to gain in depth understanding of their problems and challenges. A business case have been developed to adapt the new technology to the partner´s needs.